This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ensysce Biosciences, Inc.
Drug Names(s): PF-08
Description: PF08 is a tamper and abuse-resistant prodrug of an amphetamine currently prescribed for ADHD, using PharmacoFore's Bio-Activated Molecular Delivery (Bio-MD) system.
Bio-Activated Molecular Delivery (also referred to as Bio-MD) technology is designed to deter prescription drug abuse at a molecular level. The opioid Bio-MD systems are “activated” to release clinically effective opioid drugs only when exposed to the correct physiologic conditions (i.e., ingested).
Ensysce and Signature
In December 2015, Ensysce Biosciences and Signature Therapeutics announced the completion of a formal merger. The company will retain the name of Ensysce Biosciences and will be relocating to San Diego, California. Ensysce becomes an integrated drug delivery company for both small and large molecules.
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: